Subjects were 280 women with stage II breast cancer , out of a total of 899 , who were randomly assigned to receive CMFVP ( cyclophosphamide-methotrexate-fluorouracil-vincristine-prednisone ) for two 6-week cycles or six 4-week cycles , then subsequently randomly assigned to receive or not to receive VATH ( vinblastine-doxorubicin-thiotepa-fluoxymesterone ) .
